

# *Acta Medica Okayama*

---

*Volume 47, Issue 3*

1993

*Article 6*

JUNE 1993

---

## Therapeutic effect of neuraminidase-treated LAK cells on liver metastasis of Colon 26.

Shingo Kamitani\*      Noriaki Tanaka<sup>†</sup>      Shigeru Yunoki<sup>‡</sup>  
Akio Hizuta\*\*      Kunzo Orita<sup>††</sup>

\*Okayama University,

<sup>†</sup>Okayama University,

<sup>‡</sup>Okayama University,

\*\*Okayama University,

<sup>††</sup>Okayama University,

# Therapeutic effect of neuraminidase-treated LAK cells on liver metastasis of Colon 26.\*

Shingo Kamitani, Noriaki Tanaka, Shigeru Yunoki, Akio Hizuta, and Kunzo Orita

## Abstract

To improve the lymphokine-activated killer (LAK) cell therapy for liver metastasis, two methods which enhance accumulation of LAK cells in the liver were examined for their effects on the liver metastasis of Colon 26 cancer cells in BALB/c mice. Distribution of LAK cells in the mice was examined by the  $^{51}\text{Cr}$  labeling method. Portal vein infusion of LAK cells or tail vein infusion of neuraminidase treated-LAK (N-LAK) cells showed an augmented accumulation of infused cells in the liver. In the first experiment, LAK cells ( $5 \times 10^7$  cells) were infused in the portal vein or tail vein at days 3 and 7 after the inoculation of  $5 \times 10^4$  tumor cells and  $1 \times 10^4$  units of IL-2 were given three times a day from day 3 to day 7. The portal infusion of LAK cells produced a greater reduction of liver metastases compared with the peripheral infusion. In the second experiment,  $5 \times 10^7$  LAK cells or N-LAK cells were infused via the tail vein on days 1 and 3, and  $1 \times 10^4$  units of IL-2 were given once a day from day 1 to day 5 after the inoculation of  $1 \times 10^4$  tumor cells. The therapeutic effect of N-LAK cells was greater than non-treated LAK cells on the number of metastatic lesions and the survival time of mice. Since access to the human portal vein is difficult and risky in clinical situation, peripheral infusion of N-LAK cells is preferable.

**KEYWORDS:** ILAK cell, neuraminidase, liver metastasis

---

\*PMID: 8379346 [PubMed - indexed for MEDLINE]

## Therapeutic Effect of Neuraminidase-Treated LAK Cells on Liver Metastasis of Colon 26

Shingo Kamitani, Noriaki Tanaka\*, Shigeru Yunoki, Akio Hizuta and Kunzo Orita

First Department of Surgery, Okayama University Medical School, Okayama 700, Japan

To improve the lymphokine-activated killer (LAK) cell therapy for liver metastasis, two methods which enhance accumulation of LAK cells in the liver were examined for their effects on the liver metastasis of Colon 26 cancer cells in BALB/c mice. Distribution of LAK cells in the mice was examined by the  $^{51}\text{Cr}$  labeling method. Portal vein infusion of LAK cells or tail vein infusion of neuraminidase treated-LAK (N-LAK) cells showed an augmented accumulation of infused cells in the liver. In the first experiment, LAK cells ( $5 \times 10^7$  cells) were infused in the portal vein or tail vein at days 3 and 7 after the inoculation of  $5 \times 10^4$  tumor cells and  $1 \times 10^4$  units of IL-2 were given three times a day from day 3 to day 7. The portal infusion of LAK cells produced a greater reduction of liver metastases compared with the peripheral infusion. In the second experiment,  $5 \times 10^7$  LAK cells or N-LAK cells were infused via the tail vein on days 1 and 3, and  $1 \times 10^4$  units of IL-2 were given once a day from day 1 to day 5 after the inoculation of  $1 \times 10^4$  tumor cells. The therapeutic effect of N-LAK cells was greater than non-treated LAK cells on the number of metastatic lesions and the survival time of mice. Since access to the human portal vein is difficult and risky in clinical situation, peripheral infusion of N-LAK cells is preferable.

**Key words :** LAK cell, neuraminidase, liver metastasis

Lymphokine-activated killer (LAK) cells are generated by cultures of normal lymphocytes with interleukin-2 (IL-2) without antigenic stimulation. They were first documented by Grimm *et al.* as activated lymphocytes having lytic activity for fresh, autologous and syngeneic cells, regardless of whether the tumor target cells were natural killer sensitive or resistant(1, 2). In animal models, transfer of LAK cells and IL-2 induced regression of pulmonary and hepatic metastasis (3). Large doses of IL-2 and LAK cells resulted in tumor regression in patients with certain advanced metastatic cancers, including renal cell carcinoma and melanoma. However, the therapeutic effects were limited to a minority of patients(4, 5), and considerable toxicity such as increase in capillary permeability accompanied the therapy (6).

Further enhancement of the therapeutic effects of

LAK cells requires study of the following two problems a) improvement of the accessibility to tumor tissues, and b) enhancement of the anti-tumor cytotoxicity. Motility is important for lymphocytes to infiltrate tumors or other inflammatory lesions. However, tumoricidal activity and motility of LAK cells are independently and sometimes inversely regulated (7). Intercellular adhesion is also important for the killing activity of lymphocytes. Neuraminidase treatment of lymphocytes increases the binding efficiency of lymphocyte subsets with endothelial cells (8). However, this treatment interferes with the normal distribution of lymphocytes in organisms, so that the majority do not home into lymphoid organs but are trapped in the liver (9). In this study, we have examined the effects of neuraminidase-treated LAK (N-LAK) cells on liver metastasis.

---

\*To whom correspondence should be addressed.

## Materials and Methods

**Animals.** Specific pathogen-free BALB/c mice between 6 and 7 weeks old, were obtained from the Shizuoka Experimental Animal Farm (Hamamatsu, Japan). Mice were housed in groups of 10 or less per cage, and fed an Oriental solid diet (Oriental Yeast Co., Tokyo, Japan).

**Tumors.** The Colon 26 (10), an undifferentiated colon adenocarcinoma generated from BALB/c mice injected with N-methyl-N-nitrosourea was cultured *in vitro* with RPMI 1640 containing 10 % fetal calf serum (FCS, Grand Island Biological Co., Grand Island, NY, USA). A single cell suspension of these cells, obtained by trypsin treatment, was injected at concentrations of  $1 \times 10^4$  or  $5 \times 10^4$  cells per BALB/c mouse body via the mesenteric vein under light ether anesthesia.

**Preparation of LAK cells.** Spleens were removed, cut finely in the medium, passed through a 150 mesh, and placed in 0.83 %  $\text{NH}_4\text{Cl}$ -Tris buffer to lyse erythrocytes, thus isolating lymphocytes. The lymphocytes were washed 3 times with Hanks balanced saline solution (HBSS) and resuspended in complete medium (CM), which was RPMI 1640 medium (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 25mM N-2-hydroxyethyl piperazine-N-2 ethane sulfonic acid (Sigma Chemical Co., St. Louis, MO, USA), 2mM L-glutamine (Wako pure Chemical Industries, Ltd., Osaka, Japan), 50  $\mu\text{M}$  2-mercaptoethanol (Sigma Chemical Co., St. Louis, MO, USA), streptomycin (100  $\mu\text{g}/\text{ml}$ ), Penicillin G (100 units) and 10 % heat inactivated FCS. Lymphocytes were cultured at a concentration of  $2.5 \times 10^6$  cells/ml in CM added with 1,000 units/ml of human recombinant IL-2 (Shionogi Pharmaceutical Co., Osaka, Japan) under 5 %  $\text{CO}_2$  in air at 37 °C for 3 days.

**Neuraminidase treatment of LAK cells.** LAK cells were incubated at  $5 \times 10^7$  cells/ml with various amounts (0.02-0.5 unit/ml) of neuraminidase (Behring Institute, Germany) at 37 °C for 30 min, and washed three times with HBSS. Cell viability, determined by Trypan-blue dye exclusion test, was not affected by this treatment.

**Assay for the distribution of infused lymphocytes.** Distribution of LAK cells was examined using normal mice without tumor inoculation. LAK cell suspension ( $5 \times 10^7$  cells) was added with 200  $\mu\text{Ci}$  of  $\text{Na}_2^{51}\text{CrO}_4$  (New England Nuclear, Boston, MA, USA) and incubated at 37 °C for 1h. The cells were then washed three times. Approximately  $2 \times 10^7$  viable cells in 0.2ml were transfused into the tail vein (peripheral infusion) or into the transposed spleen (portal infusion) of 3 mice under anesthesia with ether. Recipients were killed 24h after injection, and the liver, lungs and spleen were removed. The radioactivity of each organ was expressed as a percentage of the total radioactivity of injected cells.

**Cytotoxicity assay.** Cytotoxic function was examined by  $^{51}\text{Cr}$ -release assay. Colon 26 undifferentiated carcinoma cells (10), YAC-cells from a Molony virus-induced lymphoma in A/St mice (11), and JTC-11 cells from Ehrlich ascites tumor (12) were

labeled with radioactive chromium and used as target cells. Various numbers of effector cells were incubated with  $1 \times 10^4$   $^{51}\text{Cr}$ -labeled target cells in 0.2ml of CM in 96-well round-bottomed microtiter plates. The plates were centrifuged at 300 *g* for 5 min and incubated at 37 °C in a 5 %  $\text{CO}_2$  for 12h. After incubation, 0.1ml of the supernatant was counted in a gamma counter. Cytotoxicity was calculated by the following formula:

$$\% \text{ specific lysis} = 100 \times \frac{\text{experimental cpm} - \text{spontaneous cpm}}{\text{total cpm} - \text{spontaneous cpm}}$$

**Transposition of the spleen.** Under general anesthesia by ether, each mouse was positioned in the right decubitus, and the skin was sterilized with chlorhexidine alcohol, and a 1 cm lateral incision was made in the left subcostal arch region. The spleen was transposed to the subcutaneous region, and the peritoneum and skin were closed, leaving the spleen attached by its vascular pedicle.

**Experimental procedure.** Protocol 1 (4 groups of 5 mice each) was designed to examine the effects of the portal infusion of LAK cells via the transposed spleen. All mice were inoculated with  $5 \times 10^4$  Colon 26 cells via a mesenteric vein (day 0). LAK cells were injected at  $5 \times 10^7$  cells into the portal vein through the transposed spleen or into the tail vein on days 3 and 7. IL-2 ( $1 \times 10^4$  units in 1 ml HBSS) was given intraperitoneally every 8h for 5 days after the first transfusion of LAK cells. All were killed 14 days later, and liver metastases were assessed macroscopically. Whitish tumor nodules were mostly localized on the surface of the liver.

In protocol 2 (4 groups of 5 mice each), the effects of N-LAK cells were examined. LAK cells or N-LAK cells were injected at  $5 \times 10^7$  via the tail vein on days 1 and 3. After inoculation of  $1 \times 10^4$  tumor cells, IL-2 ( $1 \times 10^4$  units in 1 ml HBSS) was given intravenously once a day on days 1 through 5. One group of these mice was killed 21 days later, and the metastatic liver foci were examined. Another group of these mice was observed to measure their survival time.

**Statistics.** Statistical analysis was performed using Student's *t*-test.

## Results

**Lymphocyte distribution by portal and peripheral infusion.**  $^{51}\text{Cr}$ -labeled fresh lymphocytes and LAK cells were infused via the tail vein or portal vein, and the accumulation of radioactivity in the liver, spleen, and lungs was examined at 24h after infusion. As shown in Table 1, LAK cells infused via the portal vein accumulated more in the liver than LAK cells infused via the tail vein. Fresh lymphocytes showed no changes in their distribution by the route of infusion (Table 1).

**Effect of neuraminidase treatment on the cytotoxicity**

of LAK cells. After the neuraminidase treatment, LAK cells were observed to be morphologically intact and unagglutinated. The cells also showed no significant changes in the cytotoxic activity against JTC-11 and YAC-1 cells by the treatment at different concentrations between 0.01 and 0.5 units/ml of neuraminidase. The cytotoxicity of LAK cells against Colon 26 was not significantly affected by incubation with 0.5 units/ml of neuraminidase (Fig. 1)

*Effect of neuraminidase treatment on the distribution of lymphocytes examined in normal mice.* Fresh lymphocytes and LAK cells were incubated with 0.5 units/ml of neuraminidase, labeled with  $^{51}\text{Cr}$ , and trans-

fused intravenously into the normal mice in which tumor cells were not injected. The radioactivity examined at 24 h after infusion was mainly detected in the liver and spleen. The treatment of lymphocytes with neuraminidase had so altered their distribution *in vivo* that there was less radioactivity in the spleen and substantially more in the liver. Similar changes were observed in the distribution of LAK cells (Table 2).


*Augmentation of therapeutic effect on liver metastasis by portal infusion of LAK cells.* This experiment used protocol 1, and metastatic nodules were counted on day 14 for each group. The first group was infused with physiological saline solution via the tail vein, the second

**Table 1** Effect of administration route of  $^{51}\text{Cr}$ -labeled lymphocytes on accumulation of the radioactivity in tissues of recipients

Infused lymphocytes	Route of administration	Trapping rate(%) <sup>a</sup>		
		Lung	Liver	Spleen
Spleen cells	Tail vein	1.5±0.1	28.2±0.5	30.1±1.8
Spleen cells	Portal vein	1.0±0.2	23.8±1.2	37.6±1.2
LAK cells	Tail vein	3.0±0.2	37.3±3.1	32.3±3.4
LAK cells	Portal vein	6.5±1	45.3±2.2	31.2±2.6

<sup>a</sup>: Radioactivity of each organ is presented by % of the total activity of injected cells, and values are the mean ± SD of three mice.

\*  $p < 0.01$  (student's *t* test)




**Fig. 1** Effect of neuraminidase on cytotoxic activity of LAK cells. LAK: lymphokine-activated killer; N-LAK: neuraminidase treated-LAK.

**Table 2** Effect of neuraminidase treatment of  $^{51}\text{Cr}$ -labeled lymphocytes on the distribution of the radioactivity in tissues of recipients

Infused lymphocytes	Neuraminidase treatment	Trapping rate(%) <sup>a</sup>		
		Lung	Liver	Spleen
Spleen cells	-	0.64 ± 0.05	34.5 ± 0.4	29.4 ± 1.1
	+	0.70 ± 0.02	53.2 ± 2.2	13.5 ± 0.6
LAK cells	-	0.66 ± 0.01	29.1 ± 3.2	36.0 ± 0.3
	+	0.71 ± 0.02	55.7 ± 1.5	14.2 ± 0.5

<sup>a</sup>: Values are mean ± SD of three mice. \*  $p < 0.01$  (Student's *t* test)

**Fig. 2** Effect of transfusion of neuraminidase-treated LAK cells on the survival rate of tumor inoculated mice. LAK, N-LAK: See Fig. 1.

with fresh spleen cells via the portal vein, the third with LAK cells combined with IL-2 via the tail vein, and the fourth with LAK cells combined with IL-2 via portal vein. There were no significant differences between the first two groups. The experimental group infused with LAK cells via the tail vein showed significantly fewer metastases than the control group ( $p < 0.01$ ). Furthermore, the portal infusion of LAK cells led to markedly fewer metastatic nodules than the peripheral infusion ( $p < 0.05$ )(Table 3).

*Augmentation of the therapeutic effect of LAK cells on liver metastasis by in vitro neuraminidase treatment.* The experiment was conducted according to protocol 2. There was no detectable difference in the number of metastatic foci between the two groups infused with either physiological saline solution or fresh spleen cells.

Compared with the latter group, the group infused with LAK cells and IL-2 showed significant reduction in the number of metastases. Further, the group infused with N-LAK cells and IL-2 showed the greatest reduction of metastases in the three experimental groups, with 44% fewer metastases than the control (Table 4).

*Effect of LAK therapy on survival time of tumor bearing mice.* Survival studies were carried out by protocol 2. The mean survival time of the group infused with fresh lymphocytes was 32.0 days. Compared with this group, the experimental group infused with LAK cells or N-LAK cells in combination with IL-2, showed a significantly longer survival time; 37.4 days for the former and 41.6 days for the latter. The significant difference ( $p < 0.05$ ) between these two experimental groups indicat-

**Table 3** Effect of transfusion route of LAK cells on liver metastasis

Group	Route	No. of surface tumor <sup>a</sup> nodules in livers
Saline	Tail vein	> 230
Spleen cells	Portal vein	225 ± 43
LAK cells	Tail vein	98 ± 23 ] * ] *
LAK cells	Portal vein	24 ± 26 ] * ] *

<sup>a</sup>: Values are mean ± SD of 5 mice. LAK: Lymphokine activated killer.  
\*  $p < 0.01$ ; \*\*  $p < 0.05$

**Table 4** Effect of transfusion of neuraminidase treated LAK cells on liver metastasis and survival time of tumor inoculated mice

Group	No. of surface tumor <sup>a</sup> nodules in livers	Survival times <sup>b</sup> (days)
Saline	76.2 ± 7.8	31.8 ± 3.8
Spleen cells	72.2 ± 7.9 ] *	32.0 ± 3.1 ] *
LAK cells	46.4 ± 6.8 ] **	37.4 ± 3.4 ] **
N-LAK cells	33.6 ± 4.3 ] **	41.6 ± 3.8 ] **

<sup>a</sup>, <sup>b</sup>: Values are mean ± SD of 5 mice. LAK: Lymphokine activated killer; N-LAK: neuraminidase treated LAK.  
\*  $p < 0.01$ ; \*\*  $p < 0.05$

ed a therapeutic effect of N-LAK cells on liver metastasis (Fig. 2, Table 4).

## Discussion

The efficacy of cancer therapy with LAK cells depends on their cytolytic potential against tumor cells and their localization in the tumor tissue. For the latter, lymphocytes infused into a tumor-bearing host must avoid being trapped in irrelevant capillary beds, extravasate at appropriate points, and penetrate into primary or metastatic tumor masses. The efficiency of adoptive immunotherapy depends in part upon the motility of infused lymphocytes (13). However, tumoricidal lymphocytes show low activity in spontaneous motility and in chemokinetic response to IFN- $\gamma$ , showing that LAK cells may not be the best tumor infiltrators (7). The poor locomotion of tumoricidal cells is not simply due to their large size (14, 15). LAK cells are significantly less deformable than fresh NK cells and T cells (16). This increased rigidity combined with their large size may explain the

high retention of LAK cells in the lungs immediately after intravenous injection. Therefore, LAK cells should be locally infused toward the target organ having tumor metastases. In the present study, the portal infusion of LAK cells through the transposed spleen was an effective method for delivering lymphocyte to the liver. However, in the case of peripheral infusion, accumulation of LAK cells in the tumor site must be augmented by other methods; augmentation of the motility of lymphocytes, or making a tumor attract the lymphocytes. Concerning the latter method, Hosokawa *et al.* reported that combined anti-cancer chemotherapy using cyclophosphamide enhanced the accumulation of LAK cells in the tumor (17).

Surface properties of lymphocytes control their traffic and distribution in the body. Treatment with a crude glycosidase preparation (18), trypsin (19), or neuraminidase, prevents redistribution of the lymphocytes in the body. Many treated lymphocytes do not home into lymphoid organs but are trapped in the liver until normal membrane properties are recovered (20, 21). We also observed in this study that N-LAK cells were trapped more in the liver and less in the spleen. The liver was the only organ in which increased trapping was found. Neuraminidase-treated rat lymphocytes have been reported to adhere strongly to rat hepatocytes *in vitro* (22). Treatment of lymphocytes with the proteolytic enzyme or neuraminidase has been known to increase cell mediated cytotoxicity, antibody-dependent cytotoxicity (23) and NK activity (24). In the present study, cytotoxic activities of LAK cells were not augmented by neuraminidase treatment, but the infusion of N-LAK cells had a good therapeutic effect on liver metastasis. Some other mechanism may be involved in the effect. Since isolated hepatocytes are mitogens for desialyated T cells (25), accumulated T cells in the liver may be activated to produce any cytokine which may further induce killer cells. In conclusion, N-LAK cells may effectively suppress liver metastases by their enhanced accumulation in the liver.

## References

1. Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA: Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. *J Exp Med* (1982) **155**, 1823-1841.
2. Rosenstein M, Yron I, Kaufman Y and Rosenberg SA: Lymphokine-

- activated killer cells: Lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin-2. *Cancer Res* (1984) **44**, 1946-1953.
3. Shiloni E, Lafreniere R, Mule JJ, Schwarz SL and Rosenberg SA : Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice. *Cancer Res* (1986) **46**, 5633-5640.
  4. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Marston L, Inehan W, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. *N Engl J Med* (1987) **316**, 889-897.
  5. Schoof DD, Garmolini BA, Davidson DL, Massaro AF, Wilson RE and Eberlin TJ: Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. *Cancer Res* (1988) **48**, 5007-5010.
  6. Rosenstein M, Ettighausen SE and Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. *J Immunol* (1986) **137**, 1735-1742.
  7. Ratner S and Heppner GH: Motility and tumoricidal activity of interleukin-2-stimulated lymphocytes. *Cancer Res* (1988) **48**, 3374-3380.
  8. Pardi R, Bender JR, Dettori C, Giannazza E and Engleman EG: Heterogeneous distribution and transmembrane signaling properties of lymphocyte function-associated antigen (LFA-1) in human lymphocyte subsets. *J Immunol* (1989) **143**, 3157-3166.
  9. Woodruff JJ and Gesner BM: The effect of neuraminidase on the fate of transfused lymphocytes. *J Exp Med* (1969) **129**, 551-567.
  10. Corbett TH, Grisworld DP, Roberts BJ, Peckham JC and Schabel FH: Tumor induction relationship in involvement of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. *Cancer Res* (1975) **35**, 2434-2438.
  11. Sjögren HO and Hellström I: Production of polyoma specific transplantation antigenicity in Moloney leukemia cells. *Exp Cell Res* (1965) **40**, 208-215.
  12. Hamasaki M: On the properties of an established cell strain, JTC-11, from Ehrlich ascites tumor in tissue culture: 1. The characteristics of the standard strain. *Okayama-Igakkai-Zasshi* (1964) **76**, 1-11 (in Japanese).
  13. Ratner S and Heppner GH: Infiltration of transferred lymphocytes into murine mammary tumors: A locomotion-requiring process. *Proc Am Assoc Cancer Res* (1986) **27**, 362
  14. Rolstad B, Herberman RB and Reynolds CW: Natural killer cell activity in the rat: V. The circulation patterns and tissue localization of peripheral blood large granular lymphocytes (LGL). *J Immunol* (1986) **136**, 2800-2808.
  15. Maghazachi AA, Herberman RB, Vujanovic NL and Hiserodt JC: *In vivo* distribution and tissue localization of highly purified rat lymphokine activated killer (LAK) cells. *Cell Immunol* (1988) **115**, 178-194.
  16. Sasaki A, Jain RK, Maghazachi AA, Goldfarb RH and Herberman RB: Low deformability of lymphokine-activated killer cells as possible determinant of *in vivo* distribution. *Cancer Res* (1989) **49**, 3742-3746.
  17. Hosokawa M and Sawamura Y: Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. *Cancer Immunol Immunother* (1988) **26**, 250-256.
  18. Gesner BM and Ginsburg V: Effect of glycosidases on the fate of transfused lymphocytes. *Proc Natl Acad Sci USA* (1964) **52**, 750-755.
  19. Woodruff J and Gesner BM: Lymphocytes: Circulation altered by trypsin. *Science* (1968) **161**, 176-178.
  20. Freitas AA and de Sousa M: The role of cell interactions in the control of lymphocyte traffic. *Cell Immunol* (1976) **22**, 345.
  21. Woodruff JJ and Woodruff JF: Virus-induced alterations of lymphoid tissues IV: The effect of Newcastle disease virus on the fate of transfused thoracic duct lymphocytes. *Cell Immunol* (1974) **10**, 78-85.
  22. Kolb H, Kriese A, Kolb-Bachofen V and Kolb H-A: Possible mechanism of entrapment of neuraminidase-treated lymphocytes in the liver. *Cell Immunol* (1978) **40**, 457-462.
  23. Kedar E, Ortiz de Landazuri M and Fahey JL: Enzymatic enhancement of cell-mediated cytotoxicity and antibody-dependent cell cytotoxicity. *J Immunol* (1974) **112**, 26-36.
  24. Schulof RS, Fernandes G, Good RA and Gupta S: Neuraminidase treatment of human T lymphocyte's effect on Fc receptor phenotype and function. *Clin Exp Immunol* (1980) **40**, 611-619.
  25. Novogrodsky A and Ashwell G: Lymphocyte mitogenesis induced by a mammalian liver protein that specifically binds desialylated glycoproteins. *Proc Natl Acad Sci USA* (1977) **74**, 676-678.

Received November 27, 1992; accepted March 15, 1993.